Table 2. Univariate and multivariate analysis of factors associated with overall survival of patients with TSCC.

Vavirable	Cases number	HR(95%C1)	P
Univariate analysis Sex Male vs Female	71/61	1.067(0.572-1.990)	0.813
Age(years) <50 vs ≥250	47/85	1.224(0.798-1.877)	0.312
Node metastasis N0 vs N +	59/73	1.461(1.014-2.105)	0.037
Clinical stage III VS IV	81/51	2.042(1.416-2.945)	0.000
Cisplatin Sensitive vs Non-sensitive	70/62	0.710(0.516-0.976)	0.043
MFF Low vs High	57/75	1.621(1.194-2.201)	0.010
miR-593-5p Low vs High	78/54	1.545(1.097-2.176)	0.028
BRCAI Low vs High	83/49	1.704(1.225-2.370)	0.007
Multivariate analysis Node metastasis NO vs N+	59/73	1.472(1.031-2.101)	0.041
Clinical stage III VS IV	81/51	2.325(1.476-3.662)	0.000
Cisplatin Sensitive vs Non-sensitive	70/62	0.527(0.358-0.776)	0.035
MFF Low vs High	57/75	1.837(1.105-3.175)	0.017
BRCAI Low vs High	83/49	2.053(1.284-3.283)	0.007